39
https://pubmed.ncbi.nlm.nih.gov/38116691
The abstract reports that in high-risk people with type 2 diabetes, eGFR, UACR, and KDIGO category have distinct relationships with cardiovascular and kidney outcomes, and that efpeglenatide has a beneficial effect on these outcomes that is independent of kidney-related risk category.